Loading clinical trials...
Loading clinical trials...
A Phase 1, Open-Label Study to Determine the Effect of Calories and Fat Content on the Pharmacokinetics of Repeated Dose Lurasidone 120 mg in Subjects With Schizophrenia, Schizoaffective Disorder, or Schizophreniform Disorder.
The objective of this study is to evaluate the effect of calorie and fat content on the pharmacokinetics of Lurasidone HCl in subjects with schizophrenia, schizoaffective disorder, or schizophreniform disorder.
Age
18 - 65 years
Sex
ALL
Healthy Volunteers
No
California Clinical Trials
Glendale, California, United States
Clinical Research Institute
Wichita, Kansas, United States
Start Date
May 1, 2009
Primary Completion Date
September 1, 2009
Completion Date
September 1, 2009
Last Updated
September 8, 2011
26
ACTUAL participants
Lurasidone HCl
DRUG
Lead Sponsor
Sumitomo Pharma America, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions